168 related articles for article (PubMed ID: 34397130)
1. The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials.
Hayes AR; Chan DLH; Chan BA; Pavlakis N
J Neuroendocrinol; 2021 Sep; 33(9):e13015. PubMed ID: 34397130
[TBL] [Abstract][Full Text] [Related]
2. Quality of clinical trials in gastroenteropancreatic neuroendocrine tumours.
Walter T; Krzyzanowska MK
Neuroendocrinology; 2012; 96(3):238-48. PubMed ID: 22414794
[TBL] [Abstract][Full Text] [Related]
3. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
Monzon JG; Hay AE; McDonald GT; Pater JL; Meyer RM; Chen E; Chen BE; Dancey JE
Eur J Cancer; 2015 Nov; 51(17):2501-7. PubMed ID: 26338195
[TBL] [Abstract][Full Text] [Related]
4. Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research.
Felix A; Berlanga P; Toulmonde M; Landman-Parker J; Dumont S; Vassal G; Le Deley MC; Gaspar N
Cancer Med; 2021 Mar; 10(5):1589-1604. PubMed ID: 33452711
[TBL] [Abstract][Full Text] [Related]
5. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
6. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines.
Mistry P; Dunn JA; Marshall A
BMC Med Res Methodol; 2017 Jul; 17(1):108. PubMed ID: 28720094
[TBL] [Abstract][Full Text] [Related]
7. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
Kulke MH; Siu LL; Tepper JE; Fisher G; Jaffe D; Haller DG; Ellis LM; Benedetti JK; Bergsland EK; Hobday TJ; Van Cutsem E; Pingpank J; Oberg K; Cohen SJ; Posner MC; Yao JC
J Clin Oncol; 2011 Mar; 29(7):934-43. PubMed ID: 21263089
[TBL] [Abstract][Full Text] [Related]
8. Comparison of treatment effect from randomised controlled phase II trials and subsequent phase III trials using identical regimens in the same treatment setting.
Liang F; Wu Z; Mo M; Zhou C; Shen J; Wang Z; Zheng Y
Eur J Cancer; 2019 Nov; 121():19-28. PubMed ID: 31526874
[TBL] [Abstract][Full Text] [Related]
9. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.
Fazzari M; Heller G; Scher HI
Control Clin Trials; 2000 Aug; 21(4):360-8. PubMed ID: 10913810
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
[TBL] [Abstract][Full Text] [Related]
11. State of the art and future directions in the systemic treatment of neuroendocrine neoplasms.
Jungels C; Deleporte A
Curr Opin Oncol; 2021 Jul; 33(4):378-385. PubMed ID: 33973550
[TBL] [Abstract][Full Text] [Related]
12. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
Lamarca A; Barriuso J; Kulke M; Borbath I; Lenz HJ; Raoul JL; Meropol NJ; Lombard-Bohas C; Posey J; Faivre S; Raymond E; Valle JW
Br J Cancer; 2018 Jan; 118(2):181-188. PubMed ID: 29161241
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
Lamarca A; Elliott E; Barriuso J; Backen A; McNamara MG; Hubner R; Valle JW
Cancer Treat Rev; 2016 Mar; 44():26-41. PubMed ID: 26855376
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the quality of the reporting of phase II clinical trials in oncology: A systematic review.
Rivoirard R; Langrand-Escure J; Oriol M; Tinquaut F; Chauvin F; Rancoule C; Magné N; Bourmaud A
Crit Rev Oncol Hematol; 2018 May; 125():78-83. PubMed ID: 29650280
[TBL] [Abstract][Full Text] [Related]
15. What have we learnt from previous phase II trials to help in the management of childhood brain tumours?
Chastagner P; Bouffet E; Grill J; Kalifa C
Eur J Cancer; 2001 Nov; 37(16):1981-93. PubMed ID: 11597375
[TBL] [Abstract][Full Text] [Related]
16. Prospective clinical trials of biotherapies in solid tumors: a 5-year survey.
Ottaiano A; Mollo E; Di Lorenzo G; Pisano C; Di Maio M; Barletta E; Pensabene M; Segati R; Bullian P; Nasti G; Bryce J; Scala S; Castello G; Ascierto PA
Cancer Immunol Immunother; 2005 Jan; 54(1):44-50. PubMed ID: 15693138
[TBL] [Abstract][Full Text] [Related]
17. Current Landscape of Late-Phase Clinical Trials for Alzheimer's Disease: Comparing Regional Variation Between Subjects in Japan and North America.
Kikuchi M; Adachi N; Matsumaru N; Tsukamoto K
Pharmaceut Med; 2019 Dec; 33(6):511-518. PubMed ID: 31933241
[TBL] [Abstract][Full Text] [Related]
18. Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations.
Gewandter JS; Dworkin RH; Turk DC; Devine EG; Hewitt D; Jensen MP; Katz NP; Kirkwood AA; Malamut R; Markman JD; Vrijens B; Burke L; Campbell JN; Carr DB; Conaghan PG; Cowan P; Doyle MK; Edwards RR; Evans SR; Farrar JT; Freeman R; Gilron I; Juge D; Kerns RD; Kopecky EA; McDermott MP; Niebler G; Patel KV; Rauck R; Rice ASC; Rowbotham M; Sessler NE; Simon LS; Singla N; Skljarevski V; Tockarshewsky T; Vanhove GF; Wasan AD; Witter J
J Pain; 2020; 21(9-10):931-942. PubMed ID: 31843583
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Pavel ME; Singh S; Strosberg JR; Bubuteishvili-Pacaud L; Degtyarev E; Neary MP; Carnaghi C; Tomasek J; Wolin E; Raderer M; Lahner H; Valle JW; Pommier R; Van Cutsem E; Tesselaar MET; Fave GD; Buzzoni R; Hunger M; Eriksson J; Cella D; Ricci JF; Fazio N; Kulke MH; Yao JC
Lancet Oncol; 2017 Oct; 18(10):1411-1422. PubMed ID: 28838862
[TBL] [Abstract][Full Text] [Related]
20. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
